Neuro Imaging (including dementia imaging)
The clinic of nuclear medicine has a long experience in the area of brain imaging, as well with Single Photon Emission Tomography (SPECT) as with Positron Emission Tomography (PET). Today the latter is used much more often than SPECT.
PET is uniquely suited to examine parameters such as perfusion and metabolism in various diseases as well as the normal human brain. At the base of PET is the radioactive tracer which allows the imaging of the parameter of interest. At the moment we offer examinations with the following tracers.
18F Fluorodeoxyglukose (FDG)
Figure 1: Normal distribution of FDG in the human brain
FDG is a glucose analogue and is used for the following indications:
- Dementia (separation of Alzheimer's disease from other dementias)
The examination is paid by healthcare under the following provisions
- Referral by specialist FMH geriatrics, neurology or psychiatry
- Minimental Score > 10
- Duration < 5 years
- Patients age < 80
- no previous PET or SPECT examinations
- preoperative evaluation of temporal lobe epilepsy
This indication is also reimbursed by health insurance
- Movement disorders
Figure 2: MRI und FET PET of an astrocytoma WHO Grad II
FET is an amino acid analogue and is used in brain PET for the following indications, covered by health insurance for:
- Evaluation of brain tumors
- identification of biopsy location
- therapy control
- differentiation tumor vs benign lesions
Figure 3: FDOPA PET of a patient with Parkinson's disease, the tracer uptake in the right putamen is reduced
FDOPA traces the presynaptic function of the dopaminergic system. It can well differentiate between neurodegeneration and essential tremor.
Figure 4: High tracer accumulation in a meningeoma
68Ga-dotatate binds to somatostatine receptors. In the brain it is used to examine meningeomas
Figure 5: Perfusion of a patient with a stenosis of the left internal carotid
H215O is one of the best tracers to evaluate brain perfusion. We use it in patients who are candidates for a revascularisation procedure.
Amyloid PET/CT with Flutametamol (Vizamyl®)
Vizamyl® is a radioactive diagnostic agent used for positron emission tomography (PET) imaging of the brain in order to estimate the β-amyloid neuritic plaque density in adult patients with cognitive impairment who are being evaluated for Alzheimer's disease (AD) or other causes of cognitive decline.